This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective cross-sectional study, which was carried out in the area of Pelotas in Brazil. Thus, there was no explicit control group. The participants were randomly selected from 40 census sections using cluster sampling techniques. In each section, a starting point of one street block was selected at random and the first house was identified, followed by systematic sampling of the next 30 houses. The patients were not followed up. The patients were interviewed using a standardised pre-coded questionnaire and blood pressure was measured at home. All of the interviewers were trained and certified in the technique of interviewing and taking blood pressure measurements. The supervisors reviewed the questionnaire by repeating 10% of the interviews at random using a short version of the questionnaire.
Analysis of effectiveness
All of the patients included in the final sample were considered in the effectiveness study. The outcome measures were the rate of patients with hypertension, the proportion of patients using each antihypertensive therapy, and the percentage of patients with controlled hypertension.
Effectiveness results
The percentage of patients with hypertension was 23.5% (462 out of 1,968).
Diuretics were used in 27.4%, beta-blockers in 12%, calcium-channel blockers in 3%, ACE inhibitors in 9.7%, diuretics plus beta-blockers in 13.9%, diuretics plus calcium-channel blockers in 5%, diuretics plus ACE inhibitors in 11.6%, beta-blockers plus calcium-channel blockers in 2.3%, beta-blockers plus ACE inhibitors in 1.2%, and other combinations in 13.1%.
The mean percentage of patients with controlled hypertension was: 54.9% (95% confidence interval, CI: 43.3 -66.5) for diuretics, 71% (95% CI: 55 -86.9) for beta-blockers, 80% (95% CI: 55.2 -104.7) for calcium-channel blockers, and 52% (95% CI: 32.4 -71.6) for ACE inhibitors; 55.6% (95% CI: 39.3 -71.8) for diuretics plus beta-blockers, 61.5% (95% CI: 35.1 -88) for diuretics plus calciumchannel blockers, 36.7% (95% CI: 19.4 -53.9) for diuretics plus ACE inhibitors, 50% (95% CI: 10 -90) for betablockers plus calcium-channel blockers, and 66.7% (95% CI: 13.3 -120) for beta-blockers plus ACE inhibitors; 47% (95% CI: 30.3 -63.8) for other combinations.
Clinical conclusions
The effectiveness analysis showed that hypertension control was obtained more frequently with calcium-channel blockers and beta-blockers than with diuretics and ACE inhibitors.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was the percentage of patients with controlled hypertension. This was derived directly from the effectiveness study.
Direct costs
Discounting was not relevant because the costs were incurred during one year. The unit costs were not reported separately from the quantities of resources used. The health services included in the economic analysis were drugs, health insurance, medical consultations, laboratory tests, and transportation and meals. The cost/resource boundary adopted in the study was not explicitly stated, but it appears to have been that of the patient.
Resource use was estimated using data gathered through questionnaires alongside the effectiveness study from December 1999 to April 2000. A group of 259 patients who had a medical appointment within the month preceding the interview was included in the analysis. The unit costs were based on the average official cost for each drug class, and on patient reports for the other cost components. The price year was 2002. Monthly mean costs were calculated to compare the costs of hypertension treatment with those associated with diabetes and bronchitis care. The annual therapy costs were calculated for each class of antihypertensive treatment.
Statistical analysis of costs
No statistical test of the costs was conducted, but the costs were presented as mean values with standard deviations.
Indirect Costs
Indirect costs were included in the analysis. These were calculated from workdays lost due to disease, medical consultations, or performing tests. The unit cost was estimated from the proportional per-capita income earned during one working day in Brazil. However, the unit costs were not analysed separately from the quantities of resources used. Discounting was not relevant and was not carried out. Although not explicitly stated, it appears that 2002 prices have been used.
Currency
Brazilian reais (R$).
Sensitivity analysis
Sensitivity analyses were not carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The estimated annual costs were: 
Synthesis of costs and benefits
An average cost-effectiveness ratio was calculated to combine the costs and benefits of the antihypertensive therapies. A cost-effectiveness analysis, stratified by co-morbidities (diabetes or smoking), was also conducted. This showed that a less favourable cost-effectiveness relationship was observed for monotherapy with beta-blockers (R$321 versus R$215.28) and diuretics (R$127.98 versus R$109.88) or in association (R$388.06 versus R$299.15).
Patients without co-morbidities were associated with a less advantageous cost-effectiveness ratio for ACE inhibitors (R$869.73 versus R$487.73) and calcium-channel blockers (R$1,052.59 versus R$629.68).
